An international consensus approach to the management of atypical hemolytic uremic syndrome in children
Top Cited Papers
- 11 April 2015
- journal article
- practice guideline
- Published by Springer Science and Business Media LLC in Pediatric Nephrology
- Vol. 31 (1), 15-39
- https://doi.org/10.1007/s00467-015-3076-8
Abstract
Atypical hemolytic uremic syndrome (aHUS) emerged during the last decade as a disease largely of complement dysregulation. This advance facilitated the development of novel, rational treatment options targeting terminal complement activation, e.g., using an anti-C5 antibody (eculizumab). We review treatment and patient management issues related to this therapeutic approach. We present consensus clinical practice recommendations generated by HUS International, an international expert group of clinicians and basic scientists with a focused interest in HUS. We aim to address the following questions of high relevance to daily clinical practice: Which complement investigations should be done and when? What is the importance of anti-factor H antibody detection? Who should be treated with eculizumab? Is plasma exchange therapy still needed? When should eculizumab therapy be initiated? How and when should complement blockade be monitored? Can the approved treatment schedule be modified? What approach should be taken to kidney and/or combined liver–kidney transplantation? How should we limit the risk of meningococcal infection under complement blockade therapy? A pressing question today regards the treatment duration. We discuss the need for prospective studies to establish evidence-based criteria for the continuation or cessation of anticomplement therapy in patients with and without identified complement mutations.Keywords
This publication has 128 references indexed in Scilit:
- A systematic review of eculizumab for atypical haemolytic uraemic syndrome (aHUS)BMJ Open, 2013
- Long‐term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuriaBritish Journal of Haematology, 2013
- Determining the Population Frequency of the CFHR3/CFHR1 Deletion at 1q32PLOS ONE, 2013
- Recessive mutations in DGKE cause atypical hemolytic-uremic syndromeNature Genetics, 2013
- Long-term eculizumab improves clinical outcomes in atypical hemolytic uremic syndromePediatric Nephrology, 2012
- Atypical hemolytic uremic syndrome in children: complement mutations and clinical characteristicsPediatric Nephrology, 2012
- Atypical hemolytic uremic syndromeOrphanet Journal of Rare Diseases, 2011
- CD46-associated atypical hemolytic uremic syndrome with uncommon course caused by cblC deficiencyPediatric Nephrology, 2010
- Prevention of large-vessel stenoses in atypical hemolytic uremic syndrome associated with complement dysregulationPediatric Nephrology, 2010
- Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndromeBlood, 2010